Early Results: “ROCKET” a phase II study of RRx-001, a novel triple epigenetic inhibitor. Resensitization to irinotecan in colorectal cancer

Date 02 March 2015
Event 13th International Congress on Targeted Anticancer Therapies
Session Phase 1 studies: Miscellaneous drugs & targets
Topics Anti-Cancer Agents & Biologic Therapy
Drug Development
Colon Cancer
Rectal Cancer
Presenter Corey Carter